IBEC researchers find a new way to effectively transport drugs to the brain

by IBEC - Institut de Bioenginyeria de Catalunya

4 years ago
transport, drugs, brain

An international group of researchers from the University of Maryland (United States) and the Institute for Bioengineering of Catalonia (IBEC) led by ICREA Research Professor Silvia Muro, has identifi...

Alliance between the IMIM and Chemotargets to accelerate the design of new cancer therapies

by Parc Científic de Barcelona

4 years ago
IMIM, Chemotargets, intelligence platforms, personalized medicine, drugs, cancer

The company Chemotargets –based in the Barcelona Science Park and a leader in in the global market as a provider of intelligence and drug design prediction platform– has signed a strategic agreeme...

Alta Life Sciences and CDTI invest €7.6M in Accure Therapeutics, a new company that will develop a portfolio of new medicines to address CNS diseases

by Alta Life Sciences / CDTI

4 years ago
Alta Life Sciences, CDTI, Accure Therapeutics, drugs, Central Nervous System

Accure Therapeutics, a new pharma R&D player in the Central Nervous System (CNS) field, announces today its launch with a Series A round of funding totalling €7.6 million ($8.1M). The funding round ...

The desperate use of drugs against coronavirus should be rationalized – Press release El PAÍS

by Som Biotech

4 years ago
cancer, hyperlipidemia, technology, coronavirus, drugs

SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment fo...

When Standardization Meets Customization

by Pall Biotech

4 years ago
biocontainers, standardization, customization, patent, drugs, technologies

To bring your biologic to market as quickly as possible, streamlined scale up is essential. By combining standardized, single-use platform technologies that can be customized to your particular proces...

The FDA licenses Chemotargets CLARITY platform

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

4 years ago
FDA, Chemotargets, drugs, molecular

Chemotargets -a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park- has signed a license agreement for its CLARITY® pla...

IRB Barcelona collaborates with Amazon in the development of a computational tool to speed up the search for drugs against COVID-19

by IRB Barcelona - Instituto de Investigación Biomédica

4 years ago
Chemical Checker, covid-19, artificial intelligence, drugs, Amazon

There are currently more than 10,000 scientific articles related to coronavirus infections. In fact, in recent weeks, research to combat COVID-19 has accelerated, and more than 4,000 new academic pape...

Who is conducting clinical research?

by Centro de Oftalmología Barraquer

4 years ago
financial gain, clinical research, drugs, pharmaceutical industry

Clinical research is a collaborative process carried out by multidisciplinary teams with the technical and logistic support of all staff from the Barraquer Ophtalmology Center

A research team develop biotransistors able to hear small beats of live

by IBEC - Institut de Bioenginyeria de Catalunya

4 years ago
biotransistors, beat, drugs, electrocardiogram, micro-tissues

Researchers at IBEC and ICMAB develop a flexible, cheap and biocompatible transistor platform able to record an electrocardiogram of cells and micro-tissues during long periods of time.

IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications

by Hospital Universitari de Bellvitge

4 years ago
IDIBELL, Pharmacelera, drugs, cancer, cohesin

Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block the cohesin complex, with applications in seve...

Antonio Juárez 'We still use the same antibiotics as decades ago, and this has helped bacteria become resistant'

by Fundació Bosch i Gimpera

5 years ago
antibiotics, drugs, resistence

Dr. Antonio Juárez signed his first knowledge transfer contract thirty years ago, and since then he has continued to collaborate with companies and institutions in the field of microbiology. Now his ...

Study the use of beta-lactam monotherapy in bacteremia caused by Pseudomonas aeruginosa

by Instituto de Investigación Marqués de Valdecilla

5 years ago
bacteremia, drugs, monotherapy, beta-lactam

IDIVAL researchers belonging to the group of Epidemiology and Pathogenic and Molecular Mechanisms of Infectious Diseases and Microbiology led by Dr. Carmen Fariñas, head of the Infectious Se...